NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $14.68 -0.33 (-2.20 %) (As of 07/18/2018 06:55 AM ET)Previous Close$15.01Today's Range$14.50 - $15.3752-Week Range$3.61 - $27.06Volume751,000 shsAverage Volume983,546 shsMarket Capitalization$238.78 millionP/E RatioN/ADividend YieldN/ABeta2.65 Company ProfileFinancialsAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd. Receive GLMD News and Ratings via Email Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:GLMD CUSIPN/A Webwww.galmedpharma.com Phone972-3693-8448 Debt Debt-to-Equity RatioN/A Current Ratio5.90 Quick Ratio5.90 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.09 million Price / Sales214.27 Cash FlowN/A Price / CashN/A Book Value$1.24 per share Price / Book11.84 Profitability EPS (Most Recent Fiscal Year)($0.98) Net Income$-12,290,000.00 Net Margins-1,073.09% Return on Equity-110.46% Return on Assets-83.72% Miscellaneous Employees17 Outstanding Shares15,910,000Market Cap$238.78 Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions What is Galmed Pharmaceuticals' stock symbol? Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD." How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) released its quarterly earnings data on Wednesday, May, 16th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.29 million. Galmed Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 1,073.09%. View Galmed Pharmaceuticals' Earnings History. When is Galmed Pharmaceuticals' next earnings date? Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Galmed Pharmaceuticals. What price target have analysts set for GLMD? 7 analysts have issued 1 year target prices for Galmed Pharmaceuticals' stock. Their predictions range from $19.00 to $59.00. On average, they expect Galmed Pharmaceuticals' stock price to reach $38.50 in the next twelve months. This suggests a possible upside of 162.3% from the stock's current price. View Analyst Ratings for Galmed Pharmaceuticals. What is the consensus analysts' recommendation for Galmed Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Galmed Pharmaceuticals stock? Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock: 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (7/11/2018) 2. Maxim Group analysts commented, "Galmed reported 3Q17, spending just $2.8M and closing the period with $9M in cash. Management was clear that with their efforts to preserve cash, they have runway through 2018 and through catalysts; data from both ARRIVE and ARREST studies." (11/9/2017) Who are some of Galmed Pharmaceuticals' key competitors? Some companies that are related to Galmed Pharmaceuticals include Karyopharm Therapeutics (KPTI), Dynavax Technologies (DVAX), MacroGenics (MGNX), Rhythm Pharmaceuticals (RYTM), CytomX Therapeutics (CTMX), Assembly Biosciences (ASMB), ANI Pharmaceuticals Inc Common Stock (ANIP), Amarin (AMRN), Homology Medicines (FIXX), NuCana (NCNA), Eidos Therapeutics (EIDX), Inflarx (IFRX), Rocket Pharmaceuticals (RCKT), Kiniksa Pharmaceuticals (KNSA) and CymaBay Therapeutics (CBAY). Who are Galmed Pharmaceuticals' key executives? Galmed Pharmaceuticals' management team includes the folowing people: Mr. Allen Baharaff, CEO, Pres & Director (Age 53)Mr. Yohai Stenzler, CFO & Controller (Age 35)Mr. Guy Nehemya, VP of Operations (Age 33)Dr. Liat Hayardeny Ph.D., MBA, Chief Scientific Officer (Age 51)Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 35) Has Galmed Pharmaceuticals been receiving favorable news coverage? News stories about GLMD stock have trended positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Galmed Pharmaceuticals earned a coverage optimism score of 0.46 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.22 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Galmed Pharmaceuticals' stock price today? One share of GLMD stock can currently be purchased for approximately $14.68. How big of a company is Galmed Pharmaceuticals? Galmed Pharmaceuticals has a market capitalization of $238.78 million and generates $1.09 million in revenue each year. The biopharmaceutical company earns $-12,290,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe. How can I contact Galmed Pharmaceuticals? Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448. MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)Community Ranking: 3.5 out of 5 ( )Outperform Votes: 287 (Vote Outperform)Underperform Votes: 124 (Vote Underperform)Total Votes: 411MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?